Reps are motivated by the launch contest. But practitioners say it can just as easily create the wrong behavior. This report covers what commercial operations teams have to manage at launch, and where AI adoption changes the field next.
The findings in this report were drawn from a live Axtria Ignite 2026 roundtable with more than 30 IC and commercial leaders from AstraZeneca, Merck, Bristol Myers Squibb, GSK, Eli Lilly, Takeda, and other leading diagnostics and life sciences organizations.
THE PROBLEM
Three pain points leaders are working around instead of solving
- A launch contest that pushes reps to close accounts before they're ready can sour a product's standing in its own market.
- Earnings expectations set too high at launch become a retention problem once reps stop earing what they used to.
- A new C-suite leader can stack three spiffs onto one team at once, pulling reps off their customer book entirely, and operations administers the fallout.
THE ROUNDTABLE’S TENSION
What if the contest that keeps your best reps is also the one you can't defend to finance?
The 30 IC experts weighed the risks to finance before approving a contest that isn't self-funding, since a launch contest mostly rewards volume the base plan already pays for.
WHERE AI AND AGENTS ENTER THE FIELD
The roadmap isn't the open question. Adoption is.
"So how do we incentivize them behavior-wise to adopt and to change?"
- A participant, Axtria Ignite 2026 Executive Incentive Compensation Roundtable
Reps who don't use AI personally have little reason to adopt it in a regulated workflow, and that gap sits with operations, not IT. The agent model checks data quality and payouts first, then IC design, then rep inquiries.
INSIDE THE REPORT
The full launch-contest debate, the spiff-stacking example, the quarterly target-reset process for a 40-to-50-rep oncology launch, and the four-agent trust model.
GET THE REPORT
Download the full report for the launch-contest battle and the agent sequencing built to earn field trust.
WHO IT'S FOR
Written for VP+ and Director+ Sales and Commercial Operations leaders who run launches and own field execution across diagnostics and life sciences organizations. This report also resonates with Strategy and Analytics leaders who own sizing, segmentation, forecasting, and incentive design.
FAQs
